Axial spondyloarthritis — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

HardSpondyloarthropathiesAxial spondyloarthritisSCE Rheumatology

A patient with active axial spondyloarthritis has an indication for advanced therapy after conventional treatment. Which mechanism is an accepted alternative to TNF inhibition?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Interleukin-17 inhibition

The best answer is “Interleukin-17 inhibition”. IL-17 inhibitors are established advanced treatments for active axial spondyloarthritis when eligibility criteria are met, with selection informed by psoriasis, inflammatory bowel disease, uveitis and safety factors. Rituximab, IL-6 blockade, abatacept and complement inhibition are not standard effective axial-spondyloarthritis mechanisms.

Reference: NICE technology appraisal on secukinumab for axial spondyloarthritis: https://www.nice.org.uk/guidance/ta407